Longeveron
Market cap $7.1M 3.4M shares (vendor count, Nov 18, 2026) × $2.11 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
- Laromestrocel DCM Ph2/3 start2H 2026Laromestrocel DCM Ph2/3 start, 2H 2026, routine
- Company strategic review4Q 2026Company strategic review, 4Q 2026, routine
- Laromestrocel HLHS BLA filing2027Laromestrocel HLHS BLA filing, 2027, material
- Pediatric DCM Phase 2 registrational2027Pediatric DCM Phase 2 registrational, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Discontinued (1)
- Lomecel-B — Aging-related Frailty · In April 2024, we discontinued our clinical trial in Japan to evaluate laromestrocel for Aging-related Frailty.
Capital (as filed)
- Cash
- $7.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$2.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $7.2M cash, runway into the first quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (15)
- 2026-11-13 UPDATE: Longeveron (LGVN) - No Call, Open ATM 🔒 Paid
- 2026-10-27 UPDATE: Longeveron (LGVN) - The Envelope Gets Re-Opened 🔒 Paid
- 2026-09-17 UPDATE: Longeveron (LGVN) - The Envelope Opened and It Was Empty 🔒 Paid
- 2026-08-24 UPDATE: Longeveron (LGVN) - They Spent the Bullet Before the Data
- 2026-08-13 UPDATE: Longeveron (LGVN) - Four Weeks of Oxygen Left
- 2026-05-14 UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut
- 2026-05-09 UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug 🔒 Paid
- 2026-03-21 UPDATE: Longeveron (LGVN) - The 10-K Autopsy 🔒 Paid
- 2026-03-15 UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) 🔒 Paid
- 2026-03-07 UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap 🔒 Paid
- 2026-02-28 UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality 🔒 Paid
- 2026-02-14 UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing 🔒 Paid
- 2026-02-07 UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized 🔒 Paid
- 2026-01-30 UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat 🔒 Paid
- 2026-01-06 Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (15 calls)
Every verdict Biotech Distilled has published on Longeveron, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-06 Watch Longeveron Inc (LGVN): Scientific Deep Dive for Lead and Pipeline Products The HLHS science is intriguing but the dilution gap — cash runway ending Q1 2026 while the pivotal data readout is Q3 2026 — is a structural barrier to entry; wait for the inevitable financing to clear before re-evaluating.
- 2026-01-30 Watch UPDATE: Longeveron (LGVN) - Regulatory Momentum & Manufacturing Moat FDA Type C meeting and Japan patent strengthen the regulatory and manufacturing story, but the balance sheet risk remains the gatekeeper; continue to wait for the Q1 2026 financing to clear.
- 2026-02-07 Watch UPDATE : Longeveron (LGVN) - Rare Pediatric Disease PRV Program Reauthorized PRV program reauthorization through 2029 secures the $150M+ voucher optionality, but the dilution gap remains the primary risk; still waiting for the capital raise to clear before entering.
- 2026-02-14 Watch UPDATE: Longeveron (LVGN) - The Financial Fire Alarm is Ringing The 8-K confirming 50% pay cuts, furloughs, and institutional capitulation validates the acute cash crisis; stay on the sidelines and let the dilutive financing event happen before evaluating entry.
- 2026-02-28 Watch UPDATE: Longeveron (LGVN) - Scientific Validation vs. Financial Reality The Cell Stem Cell frailty publication is scientific validation but not a buy signal; it reads as a pre-financing stock-support maneuver, and the dilution gap remains the primary focus.
- 2026-03-07 Watch UPDATE: Longeveron (LGVN) - The Reverse Stock Split and the Dilution Trap The reverse split proxy reveals the mechanism for massive upcoming dilution; the company is actively negotiating financing now, so stay on the sidelines until the deal is announced and the dust settles.
- 2026-03-15 Speculative buy speculative UPDATE: Longeveron (LGVN) - Surviving the Gap (But Pawning the Crown Jewel) The $15M private placement removes near-term bankruptcy risk and funds the company to the Q3 2026 ELPIS II readout, making a run-up trade active, though the diluted cap table and pawned PRV upside lower the ceiling materially.
- 2026-03-21 Speculative buy speculative UPDATE: Longeveron (LGVN) - The 10-K Autopsy The 10-K confirms the cash crunch narrative and the punishing financing terms, but the Coastland/Janus deal extended runway into Q4 2026; hold for the pre-data run-up with disciplined exit targets given diluted cap table and forfeited PRV upside.
- 2026-05-09 Avoid UPDATE: Longeveron (LGVN) - The FDA Pulls the Pivotal Rug The FDA's Type C meeting revoked ELPIS II's pivotal status, struck RVEF as an inadequate primary endpoint, and refused to bless a replacement mid-trial, breaking both legs of the catalyst-trade thesis; if you bought the March squeeze, the thesis broke today.
- 2026-05-14 Avoid UPDATE: Longeveron (LGVN) - The ATM Trap Snaps Shut The Q1 10-Q reveals the ATM is frozen below $0.80 and the stock is already through that floor, narrowing financing optionality further while the Nasdaq September deadline now sits inside the post-data window; the May 8 downgrade thesis is intact and modestly hardened.
- 2026-08-13 Avoid UPDATE: Longeveron (LGVN) - Four Weeks of Oxygen Left Q2 shows $10.1M cash against a $5.7M quarterly burn with the ATM producing only $42K all quarter, the Nasdaq deadline sits nine days after the September data window, and the second $15M tranche milestone may be unreachable by its own terms; the binary event is closer with fewer chips.
- 2026-08-24 Avoid UPDATE: Longeveron (LGVN) - They Spent the Bullet Before the Data The 1-for-10 reverse split protects the Nasdaq listing ahead of the September readout but spends the only mechanical fix before the binary event, opening a one-year re-breach trapdoor where a miss triggers immediate delisting with no cure period.
- 2026-09-17 Avoid UPDATE: Longeveron (LGVN) - The Envelope Opened and It Was Empty ELPIS II missed its primary endpoint outright (p=0.8336) and the sponsor composite also failed in ITT; the 2027 BLA path, second $15M tranche, and PRV upside are all gone, leaving a strategic-review shell with roughly one quarter of cash and a $1.00 delisting trapdoor.
- 2026-10-27 Avoid UPDATE: Longeveron (LGVN) - The Envelope Gets Re-Opened A pre-specified MACE secondary hit p=0.043 (8 vs 1 events) and earned an AHA late-breaker slot, providing the best marketing material for the strategic review, but nine events after a missed primary on a company with roughly one quarter of cash and a $1.00 delisting trapdoor does not justify re-entry.
- 2026-11-13 Avoid UPDATE: Longeveron (LGVN) - No Call, Open ATM Q3 shows $7.2M cash with runway stretched to Q1 2027 partly on unpaid bills, the ATM is now unlocked with $9.3M capacity against a ~$10M market cap, a formal sale process is underway with a disclosure blackout, and common holders rank last in any transaction outcome.
- Long call · opened Mar 16, 2026 at $8.88 · closed May 11, 2026 (flipped bearish (avoid)) at $8.38 · -5.6% vs XBI +8.7%
- Avoid call · opened May 11, 2026 at $8.38 · -74.8% vs XBI +7.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We currently anticipate top-line results from ELPIS II in September 2026.”
matched to Laromestrocel (HLHS) · topline data
-
-
-
“We currently anticipate top-line results from ELPIS II in September 2026.”
matched to Laromestrocel (HLHS) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (46)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseLongeveron Announces 2026 Third Quarter Financial Results and Provides Business Updatevia aggregator→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON NOVEMBER 12, 2026→ BD updateThe Q3 10-Q puts $7.2M of cash against a runway that now ends in Q1 2027 — not Q4 2026 as last reported — but the burn math says the same thing: approximately one quarter of oxygen left. Meanwhile the CMO resigned and a second board member departed, draining governance capacity from a company already in strategic-alternatives mode and unable to hold its own earnings call.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: officer / director change
- Oct 28, 2026ReleaseLongeveron Announces Engagement of Lucid Capital Marketsvia aggregator
- Oct 26, 2026ReleaseLongeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)via aggregator→ BD updateSummary on the 8-K
- Oct 26, 20268-KCurrent report: other events · EX-99.1 PRESS RELEASE OF LONGEVERON INC., DATED OCTOBER 26, 2026→ BD updateSix weeks after ELPIS II's primary endpoint miss, a pre-specified secondary MACE endpoint has now reached statistical significance (8 SOC events vs. 1 laromestrocel, p=0.043) — and the full dataset just earned a Late-Breaking Science podium slot at the AHA. Does this reopen the regulatory door, or is it a secondary-endpoint lifeline on a sinking ship?BD extracted 1 program update from this document → LGVN pipeline
- Oct 14, 20268-KCurrent report: officer / director change
- Sep 30, 2026ReleaseLongeveron to Participate in Three Longevity/Aging Investment Conferences
- Sep 23, 20268-KCurrent report: other events · EX-99.1 PRESS RELEASE OF LONGEVERON INC., DATED SEPTEMBER 16, 2026BD extracted 1 program update from this document → LGVN pipeline
- Sep 16, 2026ReleaseLongeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)→ BD updateELPIS II missed its primary endpoint (RVEF p=0.8336), the company is exploring "all options to maximize shareholder value," and the binary event the thesis was built around has resolved — negatively. The lottery ticket didn't hit, and the escape hatches are now closed behind them.BD extracted 1 program update from this document → LGVN pipeline
- Sep 14, 20268-KCurrent report: other events
- Sep 3, 2026ReleaseLongeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 24, 2026ReleaseLongeveron Announces 1-for-10 Reverse Stock Split→ BD updateSummary on the 8-K
- Aug 24, 20268-KCurrent report: charter / bylaws / fiscal year, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AUGUST 24, 2026→ BD updateThe reverse split I flagged as a defensive pre-data warning sign just executed — 1-for-10 effective August 26 — arriving days before the September ELPIS II readout and the September 21 Nasdaq delisting deadline, confirming the structural squeeze thesis.
- Aug 19, 2026ReleaseLongeveron Appoints Nirav Jhaveri as Chief Financial Officer
- Aug 19, 20268-KCurrent report: officer / director change · EX-99.1 PRESS RELEASE
- Aug 12, 2026ReleaseLongeveron Announces 2026 Second Quarter Financial Results and Provides Business UpdateBD extracted 1 program update from this document → LGVN pipeline
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON AUGUST 12, 2026
- Aug 12, 202610-QQuarterly report
- Aug 11, 2026ReleaseLongeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global CompetitionBD extracted 1 program update from this document → LGVN pipeline
- Aug 3, 2026ReleaseLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
- Jul 29, 20268-KCurrent report: other events
- Jul 23, 2026ReleaseDeborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
- Jul 14, 20268-KCurrent report: officer / director change
- Jul 13, 2026ReleaseLongeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Pat
- Jul 8, 20268-KCurrent report: officer / director change
- Jul 6, 2026ReleaseLongeveron® Appoints Marie Washburn as Chief Financial Officer
- Jul 6, 20268-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote · EX-99.1 PRESS RELEASE DATED JULY 6, 2026
- Jun 18, 2026ReleaseNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)BD extracted 1 program update from this document → LGVN pipeline
- Jun 9, 2026ReleaseLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
- Jun 5, 20268-KCurrent report: officer / director change
- Jun 4, 2026ReleaseLongeveron to Present at BIO International Convention 2026
- May 20, 2026DEFA14AProxy soliciting material
- May 20, 2026DEF 14AProxy statement
- May 13, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MAY 13, 2026
- May 13, 202610-QQuarterly report
- May 8, 20268-KCurrent report: other events · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MAY 8, 2026
- Apr 17, 2026424B3Prospectus (resale / update)
- Apr 10, 2026S-1Registration statement
- Apr 10, 20268-KCurrent report: officer / director change
- Mar 25, 20268-KCurrent report: listing notice
- Mar 24, 20268-KCurrent report: other events
- Mar 17, 202610-KAnnual report
- Mar 12, 20268-KCurrent report: material agreement, unregistered sale of equity, charter / bylaws / fiscal year · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MARCH 10, 2026
- Mar 9, 20268-KCurrent report: listing notice, officer / director change
15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Sep 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Aug 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 10, 2026S-8Employee plan registration
- May 20, 2026ARSAnnual report to shareholders
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 5, 2026PRE 14APRE 14A
- Apr 17, 2026EFFECTRegistration effective
- Apr 15, 2026CORRESPCORRESP
- Apr 14, 2026UPLOADUPLOAD
- Mar 25, 2026DForm D (exempt offering)
- Mar 3, 2026PRE 14APRE 14A